Drug intelligence / Profile preview

TZ-93

Development stage: Preclinical
Modality: Small Molecules

Overview

TZ-93 is an experimental compound referenced alongside tripterygium wilfordii extracts and known active components such as demethylzeylasteral (DZY) and T-96, with noted anti-inflammatory activity based on preclinical research. TZ-93 has demonstrated the ability to reduce the growth of well-vascularized tumors at higher doses in preclinical models, suggesting potential use as an anti-tumor or anti-inflammatory agent. However, the precise chemical structure, molecular target, or detailed pharmacology is not clearly disclosed in available published literature.

Beyond the preview

Go deeper on TZ-93.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TZ-93.

Explore the full profile